EirGenix Inc. operates as a contract development and manufacturing company worldwide. More Details
Mediocre balance sheet with limited growth.
Share Price & News
How has EirGenix's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 6589 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 6589's weekly volatility (6%) has been stable over the past year.
7 Day Return
TW Life Sciences
1 Year Return
TW Life Sciences
Return vs Industry: 6589 underperformed the TW Life Sciences industry which returned 123.3% over the past year.
Return vs Market: 6589 exceeded the TW Market which returned 31.6% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is EirGenix's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StShould EirGenix (GTSM:6589) Be Disappointed With Their 73% Profit?
2 months ago | Simply Wall StDoes EirGenix (GTSM:6589) Have A Healthy Balance Sheet?
4 months ago | Simply Wall StThe EirGenix (GTSM:6589) Share Price Is Up 124% And Shareholders Are Boasting About It
Is EirGenix undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 6589's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 6589's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 6589 is unprofitable, so we can't compare its PE Ratio to the XA Life Sciences industry average.
PE vs Market: 6589 is unprofitable, so we can't compare its PE Ratio to the TW market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 6589's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 6589 is good value based on its PB Ratio (3.7x) compared to the XA Life Sciences industry average (4.5x).
How is EirGenix forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6589 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 6589 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 6589 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 6589's revenue (45.2% per year) is forecast to grow faster than the TW market (11.3% per year).
High Growth Revenue: 6589's revenue (45.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 6589 is forecast to be unprofitable in 3 years.
How has EirGenix performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 6589 is currently unprofitable.
Growing Profit Margin: 6589 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 6589 is unprofitable, and losses have increased over the past 5 years at a rate of 53.6% per year.
Accelerating Growth: Unable to compare 6589's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6589 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (25.8%).
Return on Equity
High ROE: 6589 has a negative Return on Equity (-47.19%), as it is currently unprofitable.
How is EirGenix's financial position?
Financial Position Analysis
Short Term Liabilities: 6589's short term assets (NT$1.8B) exceed its short term liabilities (NT$693.5M).
Long Term Liabilities: 6589's short term assets (NT$1.8B) exceed its long term liabilities (NT$1.3B).
Debt to Equity History and Analysis
Debt Level: 6589's debt to equity ratio (46.2%) is considered high.
Reducing Debt: Insufficient data to determine if 6589's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6589 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 6589 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 35.3% each year
What is EirGenix current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 6589's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 6589's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 6589's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 6589's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 6589's dividend in 3 years as they are not forecast to pay a notable one for the TW market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Cheng Liu Lee serves as Chief Executive Officer and President of EirGenix Inc. Dr. Lee has 30 years of product, process development and manufacturing experience in biotech, pharmaceutical and specialty...
|CEO & President||no data||no data||no data|
|VP & CFO||2yrs||no data||no data|
|VP & COO||2yrs||no data||no data|
|VP & CTO||2yrs||no data||no data|
|Executive Director & Chief Manufacturing Officer||1yr||no data||no data|
|Managing Director of EirGenix Europe GmbH||no data||no data||no data|
|Executive Director of Analytical Science and Quality Control||no data||no data||no data|
Experienced Management: 6589's management team is considered experienced (2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21.9%.
EirGenix Inc.'s company bio, employee growth, exchange listings and data sources
- Name: EirGenix Inc.
- Ticker: 6589
- Exchange: GTSM
- Founded: 2012
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: NT$8.059b
- Shares outstanding: 206.38m
- Website: https://www.eirgenix.com
Number of Employees
- EirGenix Inc.
- No. 101, Kangning Street
- Lane 169
- New Taipei City
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|6589||GTSM (Taipei Exchange)||Yes||Common Shares||TW||TWD||Nov 2016|
EirGenix Inc. operates as a contract development and manufacturing company worldwide. Its services include cell line development and cell bank manufacturing, process development, analytical sciences and qu...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/23 08:42|
|End of Day Share Price||2021/01/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.